These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10100910)

  • 1. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms.
    Lemmens P; Brecher M; Van Baelen B
    Acta Psychiatr Scand; 1999 Mar; 99(3):160-70. PubMed ID: 10100910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrapyramidal symptoms in patients treated with risperidone.
    Simpson GM; Lindenmayer JP
    J Clin Psychopharmacol; 1997 Jun; 17(3):194-201. PubMed ID: 9169965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
    Davidson M; Harvey PD; Vervarcke J; Gagiano CA; De Hooge JD; Bray G; Dose M; Barak Y; Haushofer M
    Int J Geriatr Psychiatry; 2000 Jun; 15(6):506-14. PubMed ID: 10861916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
    Haas M; Unis AS; Armenteros J; Copenhaver MD; Quiroz JA; Kushner SF
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):611-21. PubMed ID: 20035579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
    Fleischhacker WW; Lemmens P; van Baelen B
    Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group.
    Emsley RA
    Schizophr Bull; 1999; 25(4):721-9. PubMed ID: 10667742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous and drug-induced movement disorders in schizophrenia.
    Kopala LC
    Acta Psychiatr Scand Suppl; 1996; 389():12-7. PubMed ID: 8985472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.
    Ezewuzie N; Taylor D
    J Psychopharmacol; 2006 Jan; 20(1):86-90. PubMed ID: 16174679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
    Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
    Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Meltzer HY; Elkis H; Vanover K; Weiner DM; van Kammen DP; Peters P; Hacksell U
    Schizophr Res; 2012 Nov; 141(2-3):144-52. PubMed ID: 22954754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
    Chouinard G
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):36S-44S. PubMed ID: 7537286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal side effects and tolerability of risperidone: a review.
    Owens DG
    J Clin Psychiatry; 1994 May; 55 Suppl():29-35. PubMed ID: 7520906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
    Jeste DV; Okamoto A; Napolitano J; Kane JM; Martinez RA
    Am J Psychiatry; 2000 Jul; 157(7):1150-5. PubMed ID: 10873925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.